Table 3.
Clinicopathological characteristics in the considerable hypertrophy and minimal hypertrophy groups by univariate analysis
| Characteristics | CH (n = 15) | MH (n = 33) | P |
|---|---|---|---|
| Epidemiology | |||
| Age | 63 ± 12 | 69 ± 7 | 0.10 |
| Sex (male/female) | 11/4 | 24/9 | 0.96 |
| HBs-Ag positive (%) | 1/15 (6.7%) | 8/33 (24%) | 0.14 |
| HCV-Ab positive (%) | 0/15 (0%) | 1/33 (3%) | 0.49 |
| Biochemical factors | |||
| WBC (/μL) | 4966 ± 1198 | 6987 ± 2625 | < 0.01 |
| Hb (g/dL) | 12.4 ± 1.5 | 13.1 ± 1.0 | 0.07 |
| Plt (× 104/μL) | 23.5 ± 7.9 | 24.1 ± 7.5 | 0.81 |
| CRP (mg/dL) | 0.9 ± 1.3 | 0.9 ± 1.7 | 0.98 |
| PT (%) | 92.1 ± 27.6 | 94.5 ± 15.1 | 0.70 |
| Total bilirubin (mg/dL) | 0.98 ± 0.53 | 1.59 ± 0.94 | 0.02 |
| AST (IU/L) | 53.7 ± 27.5 | 63.4 ± 57.4 | 0.53 |
| ALT (IU/L) | 67.9 ± 51.4 | 84.3 ± 83.3 | 0.48 |
| Che (IU/L) | 231.6 ± 53.6 | 250.6 ± 66.9 | 0.33 |
| Alb (g/dL) | 3.8 ± 0.5 | 3.9 ± 0.4 | 0.36 |
| HbA1c (%) | 5.6 ± 0.9 | 5.5 ± 0.9 | 0.68 |
| ICGR15 (%) | 10.6 ± 3.7 | 16.1 ± 3.9 | < 0.01 |
| 99mTc-GSA scintigraphy | |||
| LHL15 | 0.914 ± 0.029 | 0.915 ± 0.074 | 0.95 |
| Portal pressure | |||
| PVP (cmH2O) before PTPE | 13.2 ± 2.3 | 14.1 ± 3.3 | 0.34 |
| PVP (cmH2O) after PTPE | 18.2 ± 1.9 | 20.5 ± 3.7 | 0.03 |
| Portal flow volume | |||
| IR-pFV (%) on day 1 | 112 ± 90 | 90 ± 81 | 0.40 |
| IR-pFV (%) on day 3 | 155 ± 96 | 90 ± 59 | < 0.01 |
| IR-pFV (%) on day 5 | 150 ± 108 | 111 ± 96 | 0.22 |
| IR-pFV (%) on day 7 | 160 ± 112 | 109 ± 95 | 0.11 |
| Histological factors | |||
| Fibrosis (f2,3,4) (%) | 1/15 (6.7%) | 14/33 (42.4%) | 0.01 |
HBs-Ag hepatitis B surface antigen, HCV-Ab hepatitis C virus antibody, WBC white blood cell, Hb hemoglobin, Plt platelet, CRP C-reactive protein, PT prothrombin time, AST aspartate aminotransferase, ALT alanine aminotransferase, Che cholinesterase, Alb albumin, HbA1c A1c glycated hemoglobin, ICGR15 indocyanine green retention test at 15 min, 99mTc-GSA technetium 99 m diethylenetriaminepentaacetic acid-galactosyl-human serum albumin, LHL15, receptor index: uptake ratio of the liver to that of the liver plus heart at 15 min of technetium 99 m diethylenetriaminepentaacetic acid-galactosyl-human serum albumin scintigraphy, PVP portal venous pressure, PTPE percutaneous transhepatic portal embolization, IR-pFV increase rate of portal venous flow volume